Literature DB >> 8798776

A protein kinase C translocation inhibitor as an isozyme-selective antagonist of cardiac function.

J A Johnson1, M O Gray, C H Chen, D Mochly-Rosen.   

Abstract

Protein kinase C (PKC) isozymes translocate to unique subcellular sites following activation. We previously suggested that translocation of activated isozymes is required for their function and that in addition to binding to lipids, translocation involves binding of the activated isozymes to specific anchoring proteins (receptors for activated protein kinase C. Using cultured cardiomyocytes we identified inhibitors, the V1 fragment of epsilonPKC (epsilonV1), and an 8-amino acid peptide derived from it that selectively inhibited the translocation of epsilonPKC. Inhibition of epsilonPKC translocation but not inhibition of delta or betaPKC translocation specifically blocked phorbol ester- or norepinephrine-mediated regulation of contraction. These isozyme-selective translocation inhibitors provide novel tools to determine the function of individual PKC isozymes in intact cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798776     DOI: 10.1074/jbc.271.40.24962

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  103 in total

Review 1.  Molecular biology of protein kinase C signaling in cardiac myocytes.

Authors:  A Malhotra; B P Kang; D Opawumi; W Belizaire; L G Meggs
Journal:  Mol Cell Biochem       Date:  2001-09       Impact factor: 3.396

Review 2.  Protein kinase C isozymes and addiction.

Authors:  M Foster Olive; Robert O Messing
Journal:  Mol Neurobiol       Date:  2004-04       Impact factor: 5.590

3.  Alcohol consumption enhances antiretroviral painful peripheral neuropathy by mitochondrial mechanisms.

Authors:  Luiz F Ferrari; Jon D Levine
Journal:  Eur J Neurosci       Date:  2010-08-19       Impact factor: 3.386

4.  Protein kinase C expression and subcellular distribution in chronic myocardial ischemia. Comparison of two different canine models.

Authors:  M Matejovicova; B Shivalkar; J Vanhaecke; M Szilard; W Flameng
Journal:  Mol Cell Biochem       Date:  1999-11       Impact factor: 3.396

5.  Distinct terminal and cell body mechanisms in the nociceptor mediate hyperalgesic priming.

Authors:  Luiz F Ferrari; Dioneia Araldi; Jon D Levine
Journal:  J Neurosci       Date:  2015-04-15       Impact factor: 6.167

6.  Erythropoietin induces positive inotropic and lusitropic effects in murine and human myocardium.

Authors:  David Hefer; Ting Yi; Donald E Selby; David E Fishbaugher; Sarah M Tremble; Kelly J Begin; Prospero Gogo; Martin M Lewinter; Markus Meyer; Bradley M Palmer; Peter Vanburen
Journal:  J Mol Cell Cardiol       Date:  2011-10-14       Impact factor: 5.000

7.  Rational design of a selective antagonist of epsilon protein kinase C derived from the selective allosteric agonist, pseudo-RACK peptide.

Authors:  Tamar Liron; Leon E Chen; Hanita Khaner; Alice Vallentin; Daria Mochly-Rosen
Journal:  J Mol Cell Cardiol       Date:  2007-01-24       Impact factor: 5.000

8.  Ability to induce atrial fibrillation in the peri-operative period is associated with phosphorylation-dependent inhibition of TWIK protein-related acid-sensitive potassium channel 1 (TASK-1).

Authors:  Erin Harleton; Alessandra Besana; George M Comas; Peter Danilo; Tove S Rosen; Michael Argenziano; Michael R Rosen; Richard B Robinson; Steven J Feinmark
Journal:  J Biol Chem       Date:  2012-12-10       Impact factor: 5.157

9.  Cytochrome c oxidase subunit IV as a marker of protein kinase Cepsilon function in neonatal cardiac myocytes: implications for cytochrome c oxidase activity.

Authors:  Mourad Ogbi; Catherine S Chew; Jan Pohl; Olga Stuchlik; Safia Ogbi; John A Johnson
Journal:  Biochem J       Date:  2004-09-15       Impact factor: 3.857

10.  Interleukin-1β reduces L-type Ca2+ current through protein kinase Cϵ activation in mouse heart.

Authors:  Nabil El Khoury; Sophie Mathieu; Céline Fiset
Journal:  J Biol Chem       Date:  2014-06-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.